Rare renal proximal tubular dysfunctions in primary biliary cholangitis

Ren Fail. 2024 Dec;46(1):2302409. doi: 10.1080/0886022X.2024.2302409. Epub 2024 Jan 26.

Abstract

Introduction: Renal involvement of primary biliary cholangitis (PBC) usually presents as distal renal tubular acidosis. Proximal tubular (PT) dysfunctions in PBC were rarely reported with unclear clinicopathological characteristics and renal prognosis.

Methods: We identified 11 cases of PBC with PT dysfunctions (PBC-PT). Their medical document, kidney pathology, and follow-up data were retrospectively reviewed and analyzed.

Results: The 11 PBC-PT patients were mainly middle-aged (57.8 ± 5.2 years) females (81.8%). Most of them were asymptomatic PBC (7, 63.6%) with a high prevalence of elevated serum immunoglobulin M (IgM, 81.8%) and G (IgG, 54.5%) levels. In the kidney, they had a mean estimated glomerular filtration rate (eGFR) level of 46.54 ± 23.03 ml/min/1.73m2, and 81.8% of them had eGFR below 60 ml/min/1.73m2. They showed different degrees of PT dysfunctions, including hyperuricosuria, hypouricemia, normoglycemic glycosuria, generalized aminoaciduria, hyperphosphaturia, and hypophosphatemia. Their kidney pathology showed tubulointerstitial nephritis with lymphoplasmacytic infiltrates, brush border defects, and proximal tubulitis. After glucocorticoids treatment, the PT dysfunctions manifesting as hypophosphatemia, hypouricemia, and renal glycosuria all recovered, and the eGFR levels were improved from 43.24 ± 19.60 ml/min/1.73m2 to 55.02 ± 21.14 ml/min/1.73m2 (p = 0.028), accompanied by significant improvements of serum IgM levels (from 5.97 ± 4.55 g/L to 2.09 ± 1.48 g/L, p = 0.019).

Conclusions: The PT dysfunctions were rare in PBC patients, and glucocorticoids treatment could benefit the improvements of eGFR and tubular functions.

Keywords: glucocorticoids; primary biliary cholangitis; proximal tubular dysfunctions.

MeSH terms

  • Female
  • Humans
  • Hypophosphatemia* / complications
  • Immunoglobulin M
  • Liver Cirrhosis, Biliary* / complications
  • Middle Aged
  • Nephritis, Interstitial* / pathology
  • Retrospective Studies

Substances

  • Immunoglobulin M

Grants and funding

This work was partially supported by grants from the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-173 to S.X.; 2022-PUMCH-B-019, 2022-PUMCH-D-002 to C.L.); National Natural Scientific Foundation of China (82000663 to S.X.; 82170709, 81970607 to C.L.); National Key R&D Program of China (2022ZD0116003 to C.L.); CAMS Innovation Fund for Medical Sciences (CIFMS 2021-I2M-1-003 to C.L.); Capital’s Funds for Health Improvement and Research (CFH 2020-2-4018 to C.L.); Beijing Natural Science Foundation (L202035 to C.L.); the Capital Exemplary Research Wards Project (BCRW202001 to C.L.); The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.